

**NCI DIVISION OF CANCER TREATMENT AND DIAGNOSIS  
(DCTD) FUNDING OPPORTUNITIES FOR  
EARLY PHASE THERAPEUTIC CLINICAL TRIALS**

Lori Henderson, PhD.  
Chief, Clinical Grants and Contracts Branch  
Cancer Therapy Evaluation Program, DCTD

# Investigator-Initiated Funding Opportunities

---

## (1) PAR-21-033: NCI Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

- ❖ Supports research that proposes to implement Phase 0, I, or II trials on cancer-targeted diagnostic and therapeutic interventions relevant to DCTD program areas
- ❖ Applicable to a broad range of clinical investigations to improve the diagnosis and treatment of cancer in areas of common and unmet need.
- ❖ Examples include studies to determine maximum dose, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of *novel anticancer drugs, biologics, immunotherapeutic agents, adoptive cell therapies, and drug combinations*
- ❖ Budget limited to \$499,999 in direct costs per year for up to 5 years

# Investigator-Initiated Opportunities (cont.)

---

## (2) PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

- ❖ Supports high risk, potentially breakthrough, preclinical and early phase clinical research in cancer treatment and diagnosis
- ❖ Examples of research include:
  - Exploratory, Phase I, or small Phase II trials that *test new or repurposed agents, biologics, or combinations of interventions* to:
    - ✓ Treat common or rare cancers
    - ✓ Reduce cancer therapy-related toxicity
    - ✓ Enhance the effectiveness of immune therapies
    - ✓ Reduce cancer health disparities
  - Canine trials to facilitate the development of new therapies for cancer
- ❖ Budget for these 2-year projects may not exceed \$275,000 in direct costs with no more than \$200,000 in any single year.

# Opportunities for Clinical Research Collaborations

---

## (3) PAR-20-077: NCI Investigator-Initiated Program Project Applications (P01 Clinical Trial Optional)

- ❖ Supports an integrated, collaborative research program with a well-defined, central research focus in any broad areas of cancer research – e.g., cancer diagnosis and treatment
- ❖ Research may include a *combination of basic, translational, and clinical studies involving Phase I and II clinical trials in these areas*
- ❖ Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core.
- ❖ Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

# Clinical Research Collaborations (cont.)

---

## (4) PAR-21-343 Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

- ❖ Supports applications proposing impactful, innovative collaborative research between extramural researchers and the NIH intramural investigators at the NIH Clinical Center
- ❖ Collaborative projects must align with NIH efforts to enhance the translation of discoveries into clinical applications to improve health
- ❖ Areas of Interests to NCI include: (1) Accelerating clinical evaluation of safe, effective, and durable therapeutic interventions, (2) Collaborating with clinicians in the NCI Center for Cancer Research on *clinical protocols, unique pharmaceutical agents and/or other modes of therapy, or extraordinarily rare diseases*
- ❖ Information about the NCI intramural investigators and their research interests can be found at <https://ccr.cancer.gov/>.

# Take Home Message

---

- Visit the **Division of Cancer Treatment and Diagnosis** website to learn more about the various NCI program goals, and research priorities
- Consult the scientific contact liaison listed on individual Funding Opportunity Announcements
- Contact Program Staff in the **Clinical Grants and Contracts Branch** of the Cancer Therapy Evaluation Program at NCI for more information and guidance on cancer therapy trials funded via grants and cooperative agreements

*Thank you for your attention*



*Thank you for your attention*



**NATIONAL  
CANCER  
INSTITUTE**

[www.cancer.gov](http://www.cancer.gov)

[www.cancer.gov/espanol](http://www.cancer.gov/espanol)